Document:

Amendment to Employment Agreement, dated 02/19/2010

 Exhibit 10.2 

AMENDMENT TO EMPLOYMENT AGREEMENT 

This AMENDMENT TO EMPLOYMENT AGREEMENT (“Amendment”), dated as of February 19, 2010, is by and between Neogenix Oncology,
Inc. (the “Company”) and Myron Arlen, M.D. (“you”). 
 WHEREAS, you and the Company entered into an
Employment Agreement (the “Employment Agreement”), dated as of May 5, 2009; and 
 WHEREAS, you and the Company
now desire to amend certain terms of the Employment Agreement. 
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, you and the Company agree as follows: 
 AGREEMENT 

 

	1.	Amendment to Section 3(a). The first sentence of Section 3(a) of the Employment Agreement is hereby replaced by the following:

 “The Company will pay you a base salary at the annual rate of four hundred fifty thousand dollars
($450,000)(the “Base Salary”). 
  

	2.	Amendment to Section 3(b): Section 3(b) of the Employment Agreement is hereby replaced with the following: 

“Performance Bonus. If you achieve performance targets as established by the Company on an annual basis, at the discretion of
the Compensation Committee of the Company’s Board of Directors, you shall be eligible for a performance bonus of up to fifty percent (50%) of your Base Salary for each calendar year (the “Performance Bonus”). Any Performance
Bonus shall be paid on a quarterly basis in equal amounts not to exceed twelve and one-half percent (12.5%) of your Base Salary, with each payment to be made by no later than thirty (30) days following the end of the quarter in which it is
earned.” 
  

	3.	Amendment to Section 4(d): Section 4(d) of the Employment Agreement is hereby replaced with the following: 

 

	(d)	Termination Without Cause or Due to Non-Renewal by the Company, or for Good Reason by You. If your employment hereunder is terminated either by the Company without
Cause or by you for a Good Reason, the Company will pay the Accrued Obligations to you promptly following such termination and subject to your execution in a form satisfactory to the Company (and submitted so as to be effective no later than seventy
(70) days following such termination) of a general release of claims against the Company, its officers, directors, employees, agents, subsidiaries and affiliates: 

 

	 	(i)	The Company will pay you an amount equal to the greater of the Base Salary at the rate in effect at such termination in accordance with Section 3(a) of this
Agreement for a twelve (12) period or the period remaining prior to April 30, 2012, with such amount payable in accordance with the Company’s normal payroll schedule over the course of such period. 

	 	(ii)	The Company will continue to provide you with health insurance for so long as it is obligated to continue payments equal to the Base Salary pursuant to
Section 4(d)(ii) above if you make an effective COBRA election, and provided if the duration of the base salary payments exceeds eighteen (18) months, the Company will make monthly payments in lieu of paying such premiums for the remainder
of the applicable period, subject to applicable law and the terms of the respective policies. 

No payment or benefit shall be provided under (i) or (ii) above before such
70th day following such termination, and you shall forfeit
all rights to such payments and benefits unless the Company property described in Section 8 below is returned and such release is signed and delivered (and any right to revoke has expired) before such
70th day. The first payment shall include payment of all
amounts that otherwise would have been due earlier under the terms of this Agreement had such payments commenced immediately upon such termination, and any payments made thereafter shall continue as provided above. 

 

	4.	Counterparts. This Amendment may be executed in two (2) counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument. 

  

	5.	Effectiveness of Amendment. This Amendment shall be effective, and shall become a part of the Employment Agreement, as of the date first written above upon
execution of counterparts to this Amendment by you and the Company. Except as expressly set forth herein, this Amendment shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained
in the Employment Agreement, all of which shall continue in full force and effect. 

	6.	Miscellaneous. This Amendment shall be binding upon and inure to the benefit of and be enforceable by the respective successors and assigns of the parties
hereto. The Employment Agreement, as amended by this Amendment, embodies the entire agreement and understanding among the parties hereto and supercedes all prior agreements and understandings relating to the subject matter hereof. If any provision
hereof or any application thereof shall be invalid or unenforceable, the remainder hereof and any other application of such provision shall not be affected thereby. To the extent there is any inconsistency between the terms of this Amendment and the
terms of the May 5, 2009 Employment Agreement, the terms of this Amendment shall govern. 

 IN WITNESS
WHEREOF, the parties hereto have executed this Amendment as of the date first written above. 
  

			
	NEOGENIX ONCOLOGY, INC.
	
	 /s/ Peter Gordon

	By:	 	Peter Gordon, CFO
	
	 /s/ MYRON ARLEN

	MYRON ARLEN, M.D.Employment Agreement dated May 5, 2009

 Exhibit 10.3 

 

 

 A Cancer Therapeutics & Diagnostics Company 

9700 Great Seneca Highway, Rockville, MD 20850 

phone: (240) 314 0596 

www.neogenixoncology.com 
 Philip
M. Arlen, M.D. 
 5615 Roosevelt 

Bethesda, MD 20817 

Re:        Employment Agreement 

Dear Phil: 
 This letter dated
May 5, 2009 is to confirm our understanding with respect to your employment by Neogenix Oncology, Inc. or any present or future parent, subsidiary or affiliate thereof (collectively, the “Company”). The terms and conditions agreed to
in this letter are hereinafter referred to as the “Agreement.” In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby mutually acknowledged, we have agreed as follows: 
  

	1.	Employment. 

 (a) Subject
to the terms and conditions of this Agreement, the Company will employ you, and you will be employed by the Company, as its President and Chief Medical Officer, reporting to the Board of Directors (the “Board”); provided the Company shall
promote you to Chief Executive Officer and Chief Medical Officer, reporting to the Board, by no later than April 30, 2010. You will have the responsibilities, duties and authority commensurate with the positions of President and Chief Medical
Officer. The principal location at which you will perform such services will be the Company’s facility located in Rockville, MD. Throughout the term of your employment, the Company will ensure that you are nominated, and will use its best
efforts to cause you to be elected, to serve as a Director of the Company. 
 (b) Devotion to Duties. For so long as you
are employed hereunder, you will devote substantially all of your business time and energies to the business and affairs of the Company, provided that nothing contained in this Section 1(b) will be deemed to prevent or limit your right to
manage your personal investments on your own personal time, including, without limitation, the right to make passive investments in the securities of (i) any entity which you do not control, directly or indirectly, and which does not compete
with the Company, or (ii) any publicly held entity so long as your aggregate direct and indirect interest does not exceed three percent (3%) of the issued and outstanding securities of any class of securities of such publicly held entity,
and 

 
provided, further that nothing contained herein will be deemed to prohibit you from continuing your affiliations with the National Cancer Institute, the National Institutes of Health, the
Department of Defense, the Prostate Cancer Foundation, the Gerson Lehrman Group and Forensic Medical Associates so long as such activity does not violate Sections 5, 6 or 7 hereof or substantially limit your ability to perform your full-time duties
hereunder. In addition, you may submit any new proposed collaborations or consulting positions you wish to undertake to the Neogenix Board for its approval. The approval of the Board shall not be unreasonably withheld, provided such proposed
activity would not compete with Neogenix or detract from your ability to perform your duties on behalf of Neogenix. Neogenix agrees to be supportive of your attendance at seminars, conferences and meetings which are in the Company’s interests
locally, nationally and internationally. 
  

	2.	Term of Employment. 

 (a)
Term; Termination. Subject to the terms hereof, your employment hereunder will commence on May 5, 2009 (the “Commencement Date”) and will continue until April 30, 2012; provided that if neither you nor the Company provides
the other with written notice of intent to terminate the employment relationship during the period beginning February 1, 2012 and ending March 31, 2012, your employment hereunder shall continue for one (1) additional year. The same
notice arrangement and schedule shall apply in any subsequent years. 
 Your employment hereunder will terminate upon the first
to occur of the following: 
  

	 	(i)	Immediately upon your death; 

  

	 	(ii)	By the Company: 

A. By written notice to you effective the date of such notice, following your failure, due to illness, accident or any
other physical or mental incapacity, to perform the essential functions of your position for an aggregate of ninety (90) business days within any period of one hundred eighty (180) consecutive business days during the term hereof as
determined by a physician selected by you (“Disability”), provided that if applicable law provides any provision regarding disability that is more favorable to you than that set forth herein, such more favorable provision will govern;

 B. By written notice to you effective the date of such notice, for Cause (as defined below); or 

C. By written notice to you effective thirty (30) days after the date of such notice and subject to Section 4
hereof, without Cause; or 
  

	 	(iii)	By you: 

  

	 	(A)	At any time by written notice to the Company effective thirty (30) days after the date of such notice; or 

 

	 	(B)	By written notice to the Company for Good Reason (as defined below) effective the date of such notice. 

 

 2 

 (b) Definition of “Cause”. For purposes of this Agreement,
“Cause” means (i) your commission of a felony, (ii) your willful disloyalty or deliberate dishonesty to the Company, (iii) the commission by you of an act of fraud or embezzlement against the Company, or (iv) a material
breach by you of any material provision of this Agreement which breach is not cured within thirty (30) days after delivery to you by the Company of written notice of such breach, provided that if such breach is not capable of being cured within
such thirty (30) day period, you will have a reasonable period to cure such breach but only if you promptly commence and continue good faith efforts to cure such breach. Cause shall not exist unless at least two thirds of the Board has voted in
support of such determination. With respect to any such determination, the Board will act fairly and in utmost good faith and will give you and your counsel an opportunity to appear and be heard at a meeting of the Board before the Board’s
determination becomes final. 
 (c) Definition of “Good Reason”. For purposes of this Agreement, a “Good
Reason” means any of the following, provided you inform the Company in writing of such and state your intent to end your relationship with the Company for such reason within thirty (30) days following the occurrence of any such reason and
the Company shall not within thirty (30) days of such notice remedy the condition: 
 (i) The Company’s
failure to appoint you to the positions of Chief Executive Officer and Chief Medical Officer by April 30, 2010; 

(ii) A material adverse change by the Company in your duties, authority or responsibilities which causes your positions
with the Company to become of less responsibility or authority than at the time of the Commencement Date, provided that such change is not in connection with a termination of your employment hereunder by the Company; 

(iii) A change in the lines of reporting such that you no longer report to the Board; 

(iv) The assignment to you of duties not commensurate or consistent with your positions as President and Chief Medical
Officer of the Company (or Chief Executive Officer and Chief Medical Officer, if after your appointment thereto) without your prior written consent; 

(v) A material reduction in your compensation or other benefits except such a reduction in connection with a general
reduction in compensation or other benefits of all senior executives of the Company; 
 (vi) A material breach of
this Agreement by the Company that has not been cured within thirty (30) days after written notice thereof by you to the Company; or 

(vii) Failure by the Company to obtain the assumption of this Agreement by any successor to the Company. 

 

 3 

	3.	Compensation. 

 (a)
Base Salary. The Company will pay you a base salary at the annual rate of three hundred thousand dollars ($300,000) until July 1, 2009, at which time it shall be increased to three hundred sixty thousand dollars ($360,000) (the
“Base Salary”). The Base Salary will be reviewed no less frequently than annually and may be adjusted upward at the Company’s discretion. The Base Salary will be payable in substantially equal installments in accordance with the
Company’s payroll practices as in effect from time to time. The Company will deduct from each such installment any amounts required to be deducted or withheld under applicable law or under any employee benefit plan in which you participate.

 (b) Annual Bonus. In the Company’s sole discretion, assuming you are employed by the Company as of the last day
of the relevant calendar year, you shall be eligible for an annual bonus of up to fifty percent (50%) of your Base Salary for the year that is ending (the “Annual Bonus”). Any Annual Bonus awarded shall be paid no later than sixty
(60) days following the last day of the calendar year in which it was earned. 
 (c) Vacation. You will be entitled
to paid vacation in each calendar year and paid holidays and personal days in accordance with the Company’s policies for its senior executives as in effect from time to time, but not less than twenty (20) days paid vacation in each
calendar year. Accrued unused vacation may be carried over from year to year. 
 (d) Fringe Benefits; Perquisites. You
will be entitled to participate in the same manner as other senior executives of the Company in any and all employee benefit plans which the Company provides or may establish for the benefit of its senior executives generally (including, without
limitation, group life, disability, medical, dental and other insurance, tax benefit and planning services, 401(k), retirement, pension, profit-sharing and similar plans) (collectively, the “Fringe Benefits”). In addition, throughout your
employment, the Company shall provide you with a luxury car for which the monthly payments (not including any business travel expenses reimbursed pursuant to subparagraph (e), below) would be up to one thousand five hundred dollars ($1,500) per
month if on a sixty (60) month lease. The Company shall pay such amounts directly to the lessor of the car. 
 (e)
Reimbursement of Expenses. The Company will reimburse you for all ordinary and reasonable out-of-pocket business expenses that are incurred by you in furtherance of the Company’s business in accordance with the Company’s policies
with respect thereto as in effect from time to time. 
 (f) Stock Options. In the sole discretion of the Board, you shall
be eligible for a stock option grant each year you are employed by the Company (each an “Annual Stock Option Grant”). Any Annual Stock Option Grant shall be subject to Board approval, the execution of a formal option agreement provided by
the Company and the terms and conditions of the relevant stock plan. 
  

	4.	Severance Compensation. 

(a) Definition of Accrued Obligations. For purposes of this Agreement, “Accrued Obligations,” means (i) the portion
of your Base Salary as has accrued prior to any termination 
  

 4 

 
of your employment with the Company and has not yet been paid, (ii) an amount equal to the value of your accrued unused vacation days, and (iii) the amount of any expenses properly
incurred by you on behalf of the Company prior to any such termination and not yet reimbursed. 
 (b) Death or
Disability. If your employment hereunder is terminated as a result of your death or Disability: 
 (i) The
Company will pay the Accrued Obligations to you (or your estate) promptly following such termination. 
 (ii) The
Company will continue to pay you (or your estate) an amount equal to the Base Salary at the rate in effect at the date of such termination in accordance with Section 3(a) of this Agreement for the period commencing on the date of such
termination and ending on the three (3) month anniversary of the termination date. 
 (iii) The Company will
continue to provide you or your covered beneficiaries with health insurance for so long as it is obligated to continue payments equal to the Base Salary pursuant to Section 4(b)(ii) above, subject to applicable law and the terms of the
respective policies. 
 (c) Termination for Cause or in the Absence of a Good Reason. If your employment hereunder is
terminated either by the Company for Cause or by you in the absence of a Good Reason, the Company will pay the Accrued Obligations to you promptly following such termination. 

(d) Termination Without Cause or Due to Non-Renewal by the Company, or for Good Reason by You. If your employment hereunder is
terminated either by the Company without Cause or by you for a Good Reason and subject to your execution in form satisfactory to the Company (and submitted so as to be effective no later than seventy (70) days following such termination) of a
general release of claims against the Company, its officers, directors, employees, agents, subsidiaries and affiliates in a form provided by the Company: 

(i) The Company will pay the Accrued Obligations to you promptly following such termination. 

(ii) The Company will pay you an amount equal to the greater of the Base Salary at the rate in effect at such termination
in accordance with Section 3(a) of this Agreement for a twelve (12) period or the period remaining prior to April 30, 2012, with such amount payable in accordance with the Company’s normal payroll schedule over the course of such
period. 
 (iii) The Company will continue to provide you with health insurance for so long as it is obligated to
continue payments equal to the Base Salary pursuant to Section 4(d)(ii) above if you make an effective COBRA election, and provided if the duration of the base salary payments exceeds eighteen (18) months, the Company will make monthly
payments in lieu of paying such premiums for the remainder of the applicable period, subject to applicable law and the terms of the respective policies. 
  

 5 

 (e) Payment in Lieu of Notice. In its sole discretion, the Company may, during any
period of notice relating to termination, require you to: (i) be transferred to alternative duties to be performed either at your principal office location or your residence, at the Company’s discretion; (ii) not attend your usual
place of work or any other Company premises; and/or (iii) not make contact with any employees, agents, vendors or clients of the Company, except as directed by the Company. 

(f) No Duty to Mitigate. Notwithstanding any other provision of this Agreement, (i) you will have no obligation to mitigate
your damages for any breach of this Agreement by the Company or for any termination of this Agreement, whether by seeking employment or otherwise and (ii) the amount of any benefit due to you after the date of such termination pursuant to this
Agreement will not be reduced or offset by any payment or benefit that you may receive from any other source. 
  

	5.	Prohibited Competition and Solicitation. 

(a) Certain Acknowledgements and Agreements. 

(i) You recognize and acknowledge the competitive and proprietary nature of the business of the Company. 

(ii) You acknowledge and agree that a business will be deemed competitive with the Company if it engages in a line of
business in which it performs any of the services, researches, develops or manufactures or sells any products provided or offered by the Company or under development by the Company, or any similar products or products fulfilling the same function,
whether or not similar, in the Company’s Field of Interest (such businesses to be referred to as “Competitive Businesses”). The phrase, “Field of Interest,” currently means the use of monoclonal antibody products for the
diagnosis and therapy of types of cancer related to the Hollinshead antigens. In the event the Company adopts a new definition of Field of Interest, such new definition shall be binding upon you ten (10) days after written notice to you of such
change unless you notify the Company in writing that you do not agree to such change. 
 (iii) You further
acknowledge that, while you are employed hereunder, the Company will furnish, disclose or make available to you Confidential Information (as defined below) related to the Company’s business and that the Company may provide you with unique and
specialized training. You also acknowledge that such Confidential Information and such training have been developed and will be developed by the Company through the expenditure by the Company of substantial time, effort and money and that all such
Confidential Information and training could be used by you to compete with the Company. 
 (iv) For purposes of
this Agreement, “Confidential Information,” means confidential and proprietary information of the Company, whether in written, oral, electronic or other form, including but not limited to, information and facts concerning business plans,
research, trials, advisers, customers, future customers, suppliers, licensors, licensees, partners, investors, affiliates or others, training methods and materials, financial information, 

 

 6 

 
sales prospects, client lists, inventions, or any other scientific, technical or trade secrets of the Company or of any third party provided to you or the Company under a condition of
confidentiality, provided that Confidential Information will not include information that is (1) in the public domain other than through any fault or act by you, (2) known to you prior to its disclosure to you in the course of your
employment hereunder, or (3) lawfully disclosed to you by a source other than the Company which source has a legal right to disclose such information. 

(b) Non-Competition; Non-Solicitation. During the period while you are employed hereunder and for a period of one (1) year
following the termination of your employment hereunder for any reason you will not, without the prior written consent of the Company: 

(i) For yourself or on behalf of any other, directly or indirectly, either as principal, agent, stockholder, employee,
consultant, representative or in any other capacity, own manage, operate or control, or be concerned, connected or employed by, or otherwise associate in any manner with, engage in or have a financial interest in any business whose primary line of
business is in the Field of Interest, or in any other business in which you have any direct operating or scientific responsibility in the Field of Interest anywhere in the world (the “Restricted Territory”), except that (A) nothing
contained herein shall preclude you from purchasing or owning stock in any such competitive business if such stock is publicly traded, and provided that your holdings do not exceed three (3%) percent of the issued and outstanding capital stock
of such business; (B) nothing contained herein will prevent you from engaging in a Restricted Activity for or with respect to any subsidiary, division or affiliate or unit (each, a “Unit”) of an entity if that Unit is not engaged in
any business which is competitive with the business of the Company, irrespective of whether some other Unit of such entity engages in such competition (as long as you do not engage in a Restricted Activity for such other Unit) and provided you
present a signed statement to the Company stating the name of each such Unit, the type of business conducted by each such Unit and affirming that you will not be in any way involved with the Unit(s) which are competitive with the business of the
Company; and (C) and nothing contained herein will prevent you from working in academia or government research as long as your work is not in conjunction with industry; or 

(ii) Either individually or on behalf of or through any third party, solicit, divert or appropriate or attempt to solicit,
divert or appropriate, for the purpose of competing in the Field of Interest with the Company or any present or future parent, subsidiary or other affiliate of the Company which is engaged in the Field of Interest, any joint venture or collaborative
research partners, customers or patrons of the Company, or any prospective customers or patrons with respect to which the Company has developed or made a presentation for the use or exploitation of products or processes in the Field of Interest (or
similar offering of services), located within the Restricted Territory; or 
 (iii) Either individually or on
behalf of or through any third party to (A) hire any person who is or has been in the three (3) months prior to such activity employed or otherwise engaged by the Company, (B) solicit, entice or persuade or attempt to solicit, entice
or persuade any person who is or has been in the three (3) months prior to such 
  

 7 

 
activity employed or otherwise engaged by the Company to leave the service of the Company or (C) solicit, entice or persuade or attempt to solicit, entice or persuade any person who is or
has been in the three (3) months prior to such activity employed or otherwise engaged by the Company become employed or otherwise engaged by you or any entity other than the Company. 

 

	6.	Protected Information. You will at all times, both during the period while you are employed hereunder and after the termination of your employment hereunder for
any reason, maintain in confidence and will not, without the prior written consent of the Company, use, except in the course of performance of your duties for the Company or by court order, disclose or give to others any Confidential Information.
Upon the termination of your employment hereunder for any reason, you will return to the Company all tangible Confidential Information and copies thereof (regardless of how such Confidential Information or copies are maintained).

  

	7.	Ownership of Ideas, Copyrights and Patents. 

(a) Property of the Company. All ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know-how,
inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks and formulae (collectively the “Inventions”) which may be used in the business of the Company, whether patentable,
copyrightable or not, which you may conceive (except in conjunction with permitted government activity), reduce to practice or develop while you are employed hereunder, alone or in conjunction with another or others, and whether at the request or
upon the suggestion of the Company or otherwise, will be the sole and exclusive property of the Company, and that you will not publish any of the Inventions without the prior written consent of the Company. You hereby assign to the Company all of
your right, title and interest in and to all of the foregoing. 
 (b) Notwithstanding, the terms of paragraph 7(a) of this
Agreement, nothing shall be considered an “Invention”: 
 (i) if you have developed the
“Invention” entirely on your own time without using the Company’s equipment, supplies, facility or confidential information; and 

(ii) the “Invention” does not: (A) relate to the Company’s business or actual or demonstrably
anticipated research or development; or (B) result from any work performed by any employee of or advisor to the Company. 

(c) Cooperation. At any time during your employment hereunder or after the termination of your employment hereunder for any
reason, you will make reasonable efforts to cooperate with the Company and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company’s rights in and to any of such
Inventions, including, but not limited to, joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights with respect to any such Inventions in the United States and in any and all other countries, provided that
the Company will bear the expense of such proceedings, and that any patent or other legal right so issued to you personally will be assigned by you to the Company or its designee without charge by you. The Company will

  

 8 

 
reimburse you for reasonable expenses incurred by you in connection with the performance of your obligations under this Section 7 and will compensate you at a mutually agreeable rate for any
substantial time commitment that is required following the termination of your employment relationship with the Company. 
 (d)
Licensing and Use of Innovations. With respect to any Inventions, and work of any similar nature (from any source), whenever created, which you have not prepared or originated in the performance of your employment, but which you provide to
the Company or incorporate in any Company product or system, you hereby grant to the Company a royalty-free, fully paid-up, non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose,
publish, translate, reproduce, deliver, perform, dispose of, and to authorize others so to do, all such Inventions. You will not include in any Inventions you deliver to the Company or use on its behalf, without the prior written approval of the
Company, any material which is or will be patented, copyrighted or trademarked by you or others unless you provide the Company with the written permission of the holder of any patent, copyright or trademark owner for the Company to use such material
in a manner consistent with then-current Company policy. 
 (e) Prior Inventions. Listed on Exhibit 7(e) to this
Agreement are any and all Inventions in which you claim or intend to claim any right, title and interest (collectively, “Prior Inventions”), including, without limitation, patent, copyright and trademark interests, which to the best of
your knowledge will be or may be delivered to the Company in the course of your employment, or incorporated into any Company product or system. You acknowledge that no such Inventions exist and that your obligation to disclose such information is
ongoing during the period that you provide services to the Company. 
  

	8.	Records. Upon termination of your employment hereunder for any reason or for no reason, you will deliver to the Company promptly any property of the Company
which may be in your possession, including products, materials, memoranda, notes, records, reports or other documents or photocopies of the same. 

  

	9.	General. 

 (a)
Notices. All notices, requests, consents and other communications hereunder will be in writing, will be addressed to the receiving party’s address set forth above or to such other address as a party may designate by notice hereunder, and
will be either (i) delivered by hand, (ii) sent by overnight courier, or (iii) sent by registered or certified mail, return receipt requested, postage prepaid. All notices, requests, consents and other communications hereunder will be
deemed to have been given either (i) if by hand, at the time of the delivery thereof to the receiving party at the address of such party set forth above, (ii) if sent by overnight courier, on the next business day following the day such
notice is delivered to the courier service, or (iii) if sent by registered or certified mail, on the fifth business day following the day such mailing is made. 

(b) Entire Agreement. This Agreement embodies the entire agreement and understanding between the parties hereto with respect to
the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof. No 

 

 9 

 
statement, representation, warranty, covenant or agreement of any kind not expressly set forth in this Agreement will affect, or be used to interpret, change or restrict, the express terms and
provisions of this Agreement. 
 (c) Modifications and Amendments. The terms and provisions of this Agreement may be
modified or amended only by written agreement executed by the parties hereto. 
 (d) Waivers and Consents. The terms and
provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent will be deemed to be or will
constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent will be effective only in the specific instance and for the purpose for which it was given, and will
not constitute a continuing waiver or consent. 
 (e) Assignment. The Company may assign its rights and
obligations hereunder to any person or entity that succeeds to all or substantially all of the Company’s business or that aspect of the Company’s business in which you are principally involved. You may not assign your rights and
obligations under this Agreement without the prior written consent of the Company. 
 (f) Benefit. All statements,
representations, warranties, covenants and agreements in this Agreement will be binding on the parties hereto and will inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement will be
construed to create any rights or obligations except among the parties hereto, and no person or entity will be regarded as a third-party beneficiary of this Agreement. 

(g) Governing Law. This Agreement and the rights and obligations of the parties hereunder will be construed in accordance with and
governed by the law of Maryland, without giving effect to the conflict of law principles thereof. 
 (h) Jurisdiction, Venue
and Service of Process. Any legal action or proceeding with respect to your relationship with the Company must be brought in the courts of Maryland or of the United States of America for the District of Maryland. By execution and delivery of
this Agreement, each of the parties hereto accepts for itself and in respect of its property, generally and unconditionally, the exclusive jurisdiction of the aforesaid courts. 

(i) Severability. The parties intend this Agreement to be enforced as written. However, (i) if any portion or provision of
this Agreement is to any extent be declared illegal or unenforceable by a duly authorized court having jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which
it is so declared illegal or unenforceable, will not be affected thereby, and each portion and provision of this Agreement will be valid and enforceable to the fullest extent permitted by law and (ii) if any provision, or part thereof, is held
to be unenforceable because of the duration of such provision, the geographic area covered thereby, or other aspect of the scope of such provision, the court making such determination will have the power to reduce the duration, geographic area of
such provision, or other aspect of the scope of such provision, and/or to delete specific words and phrases (“blue-penciling”), and in its reduced or blue-penciled form, such provision will then be enforceable and will be enforced.

  

 10 

 (j) Headings and Captions. The headings and captions of the various subdivisions of
this Agreement are for convenience of reference only and will in no way modify or affect the meaning or construction of any of the terms or provisions hereof. 

(k) No Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Agreement, and no course of dealing between the parties hereto, will operate as a waiver of any such right, power or remedy of the party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor
any abandonment or discontinuance of steps to enforce any such right, power or remedy, will preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a
party hereto will not constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly required under this Agreement will entitle the party receiving such notice or demand to any
other or further notice or demand in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other or further action in any circumstances without such notice or demand. 

(l) Counterparts. This Agreement may be executed in two or more counterparts, and by different parties hereto on separate
counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

(m) Section 409A Compliance. The provisions of this Agreement are intended and shall be interpreted and administered so as to
not result in the imposition of additional tax or interest under Section 409A of the Internal Revenue Code where applicable. Without limiting the foregoing, this Agreement shall not be amended in a manner so as to result in the imposition of
such tax or interest, any reference to “termination of employment” or similar term shall mean an event that constitutes a “separation from service” within the meaning of Section 409, any reimbursement of expenses shall occur
no later than the end of the calendar year following the calendar year in which is the expense is incurred (or such earlier date as applies under the Company’s business expense reimbursement policy), and if at separation from service you are
considered a Specified Employee within the meaning of said Section 409A, then any payments hereunder that are nonqualified deferred compensation within the meaning of said Section 409A that are to be made upon separation from service shall
not commence earlier than six (6) months after the date of such separation from service, and any such amounts that would otherwise be paid to you within the first six months following the separation from service shall be accumulated and
paid in a lump sum six months and one day following the separation from service (or if you die during such six-month period, as soon as practical following the date of death) 

 

 11 

 If the foregoing accurately sets forth our agreement, please so indicate by signing and
returning to us the enclosed copy of this letter. 
  

			
	Very truly yours,
	
	Neogenix Oncology, Inc.
		
	By:	 	 /s/ Peter Gordon

		 	Peter Gordon
		 	Chief Financial Officer

  

	
	Accepted and Approved
	
	 /s/ Philip M. Arlen

	Philip M. Arlen, M.D.

  

 12 

 Exhibit 7(e)—Prior Inventions 

1. none 
  

 13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]